Business of the House

Debate between Hywel Williams and Lord Lansley

Thursday 9th January 2014 Commons Chamber

[Mr Lansley]

I am glad my hon. Friend raises the Thameslink programme, which is part of the Government’s long-term strategy to transform the rail network. He and other Members will know that this is the most significant investment in rail since the 19th century. However, for all its benefits in terms of capacity and reduced journey times there is an implication for underlying costs to the system, which is why we have to look constantly at protecting the families and hard-working people who use the railways and why we have reduced the average regulated fare rise to RPI—to which he referred. We will continue to look at that. I cannot promise a debate immediately, but I can promise that my right hon. and hon. Friends at the Department for Transport will continue to look at how we can reduce underlying costs to protect those who are necessary rail users.

[Hywel Williams (Arfon) (PC)]

This week my constituents Mr and Mrs Mann were refused medication for their baby Harley by a supermarket pharmacist because the directions to the parents written by the GP were in Welsh. A greater proportion of public services are now being delivered by private organisations from outside Wales, so may we have a debate on those organisations’ adherence to the principles and requirements of the Welsh Language Act 1993?

[Mr Lansley]

This comes a short while after the sad death of Wyn Roberts, who was such a passionate advocate of the Welsh Language Act and the use of the Welsh language in services, which we have to ensure is maintained. I will raise the issue with my right hon. Friend the Secretary of State for Wales to ensure that the intentions of the Act are being seen through.

Life Sciences

Debate between Hywel Williams and Lord Lansley

Monday 5th December 2011 Commons Chamber

[Mr Lansley]

I am grateful to my hon. Friend for that point. The industry has done quite a lot in recent years in publishing more data, including data that do not necessarily support the positive case that it is looking for, because all of us, and especially those working in the field, learn a great deal and, sometimes, as much from clinical trials that produce a negative result as we do from those that produce a positive result. So, I will certainly take her point away, explore it with my colleagues and write to her if we can take further steps in that direction.

[Hywel Williams (Arfon) (PC)]

Are the patient data proposals to be England-only or UK-wide? If so, what is the relationship with projects such as the SAIL—Secure Anonymised Information Linkage—database in Swansea and Biobank? I foresee some ethical problems, as Biobank operates specifically on a voluntary basis with a written, sought-for consent. Does the Secretary of State see that there might be some problems there?